Immuron Limited IMRN
At closeNov 5, 2026, 5:47 PM EST
After hours · Nov 5, 5:47 PM ET
- YTD
- +11.39%
- 1 year
- -43.72%
- Market cap
- 6.86M
- Revenue (ttm)
- 4.90M
- Profit margin
- -141.49%
- EPS (ttm)
- -0.34
- Shares out
- 5.70M
- Forward P/E
- -198.54
- YTD return
- +11.39%
- 1-year return
- -43.72%
- Volume
- 54.21K
- Avg volume
- 2.06M
- Open
- 0.86
- Previous close
- 0.85
- Day's range
- 0.79 – 0.8601
- 52-week range
- 0.677 – 1.99
- Beta
- 1.17
- Price target
- 4.69 (+452.1%)
2Y -1.1319 (-58.05%)
Key statistics
- Enterprise value
- 435.39M
- PEG ratio
- 0.00
- Price / sales
- 2.31
- Price / book
- 35.45
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 108.60%
- Free cash flow
- -2.56M
- Total cash
- 11.66M
- Total debt
- 173.50K
- Return on equity
- -42.92%
- Short % of float
- 0.18%
- 50-day average
- 1.96
- 200-day average
- 2.38
Analyst view
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 26, 2024 | Litchfield Hills | init | — | Buy |
| Oct 18, 2017 | HC Wainwright & Co. | init | — | Buy |
About Immuron Limited
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. It also develops Travelan (IMM-124E), which is in Phase II clinical trial, to reduce the risk of contracting travelers' diarrhea; and IMM-529, which is in Phase II clinical trial, for treating patients suffering from recurring clostridium difficile infection. The company has a collaboration with the US Naval Medical Research Command and Silver Spring, MD, USA to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a research collaboration with the Walter Reed Army Institute of Research to develop three Shigella-specific therapeutic products. The company was formerly known as Anadis Limited and changed its name to Immuron Limited in December 2008. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Australia
- Website
- immuron.com.au
News
Immuron continued quarterly sales growth 
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference 
Immuron Announces Publication Of Data From Its Phase 2 Clinical Trial Of Once-Daily Oral Travelan In 'Scientific Reports'; Statistically Significant 50% Reduction In ETEC Challenge-Related Adverse Events Versus Placebo 
Travelan® Phase 2 Study Results Published 
Immuron (NASDAQ:IMRN) Sees Significant Increase in Short Interest 
Immuron (NASDAQ:IMRN) Shares Down 2.5% – What’s Next? 
12 Health Care Stocks Moving In Friday's Intraday Session 
Gold Falls Over 1%; American Outdoor Brands Shares Jump After Q1 Results 
Dow Falls Over 100 Points; US Economy Adds 162,000 Jobs In August 
Immuron Stock Surges Friday: What's Driving the Action?
Your note
Sign in to keep a note on IMRN — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Rhumbline Advisers | 0.17% | 5,939 | 11.79K | Sep 29, 2024 |
| Morgan Stanley | 0.09% | 3,333 | 6.62K | Sep 29, 2024 |
| Stephens Consulting, LLC | 0.04% | 1,500 | 2.98K | Sep 29, 2024 |